Clinical Outcome of Pacemaker paTIents according to pacing Modality and primary INDications - OPTI-MIND

Guidant Europe a Boston Scientific Company Europe0 个研究点目标入组 1,730 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patients implanted with a current Boston Scientific pacemaker (all ALTRUA models) or any future commercially available Boston Scientific PM families according to international and local guidelines for pacemaker implantation.
•2. Patients who are willing and capable of providing informed consent, participating in all testing associated with this clinical investigation at an approved clinical investigational centre;
•3. Patients whose age is 18 years or above, or of legal age to give informed consent specific to state and national law.

•1. Unable to be followed up by the participating centres for a period of two years;
•2. Current device implanted for more than 15 days;
•3. Women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physicians discretion);
•4. Patients who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the patient is participating in a mandatory governmental registry or extensions/amendments of the current protocol. Each instance should be brought to the attention of the sponsor to determine eligibility.

发起方

Guidant Europe a Boston Scientific Company Europe